Crossmark

Association of the CHG Index with the onset, progression, and prognosis of cardiovascular-kidney-metabolic syndrome: findings from two large prospective cohorts

Crossref DOI link: https://doi.org/10.1186/s13098-026-02192-2

Published Online: 2026-06-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhao, Zehao

Bai, Yingxun

Ma, Changsheng

Wang, Tianyi

Zhao, Libo

Zhao, Xiliang

Li, Quan

Ding, Yaodong

Zhang, Yang

Lin, Li

Wang, Wenjie

Han, Jiayi

Zeng, Yong
Funding

Funding for this research was provided by:

Beijing Medical Management Center (Yangfan Program (YGLX202324))

Beijing Municipal Health Bureau (YGLX202324)

Chinese Society of Cardiology (CSC2023A03)

High-Level Research Program of Beijing Anzhen Hospital (2025AZB6014)

National Natural Science Foundation of China (82070301 and 82270345)
License Information

Text and Data Mining valid from 2026-06-06

Accepted Manuscript valid from 2026-06-06
More Information

Article History

Received: 12 February 2026

Accepted: 17 May 2026

First Online: 6 June 2026

Declarations

:

: The UK Biobank study received ethical approval from the North West Multi-centre Research Ethics Committee (MREC). This specific research was conducted using the UK Biobank Resource under Application Number 103736. The Anzhen cohort study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Beijing Anzhen Hospital, Capital Medical University (approval No. KS2023081). Written informed consent was obtained from all participants prior to participation.

: All participants provided informed electronic consent at recruitment.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below